134
Participants
Start Date
August 12, 2019
Primary Completion Date
June 3, 2025
Study Completion Date
June 3, 2025
Ocrelizumab
Administered by subcutaneous Injection
Ocrelizumab
Administered by Intravenous (IV) Injection
rHuPH20
Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
Columbia University Medical Center, New York
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Georgetown University Medical Center, Washington D.C.
John Hopkins University School of Medicine, Baltimore
Neurology Clinic PC, Cordova
Cleveland Clinic Mellen Center, Cleveland
UC Health Neurology, Dayton
Wayne State University, Detroit
Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis, Owosso
Washington Univ School of Med, St Louis
Ochsner Clinic Foundation, New Orleans
The NeuroMedical Clinic of Central Louisiana, Alexandria
University of Texas at Houston, Houston
University of Colorado, Aurora
Swedish Neuroscience Institute, Seattle
MultiCare Health System Institute for Research and Innovation, Tacoma
University of Massachusetts Medical School, Worcester
Hoffmann-La Roche
INDUSTRY